Please note: Forest Laboratories, Inc. is not responsible for
the content or services on the site you will now visit.
TEFLARO IS INCLUDED IN CORE MEASURES EFFECTIVE FOR DISCHARGES BEGINNING JANUARY 1, 2012
TEFLARO® (ceftaroline fosamil) is one of the recommended β-lactam antibiotics for Community-Acquired Pneumonia in Immunocompetent Patients—Non-ICU Patients.*
On July 1, 2011, TEFLARO was added to the Inpatient Quality Reporting (IQR) Program Specifications Manual 4.0 as one of the recommended β-lactam antibiotics in the Pneumonia Core Measure.*
The inclusion is effective for patient discharges occurring on or after January 1, 2012.*
Have you received internal guidance regarding the addition of TEFLARO to the IQR Program Core Measures?
You may want to alert your hospital's quality improvement department or another appropriate individual, committee, or department within the hospital that manages quality reporting requirements.
Refer to the Core Measures website, http://www.jointcommission.org/pneumonia; click on Specifications Manual for National Hospital Inpatient Quality Measures, Version 4.0 for details regarding PN-6b.
For additional information, contact the TEFLARO Reimbursement Hotline at 855-284-1818.
*TEFLARO is indicated for ABSSSI due to MRSA. It is not indicated for CABP due to MRSA. MSSA=Methicillin-susceptible Staphylococcus aureus. MRSA=Methicillin-resistant Staphylococcus aureus. *There are insufficient historical data to establish the magnitude of drug effect for antibacterial drugs compared with placebo at a TOC time point. Etest® is a registered trademark of BioMérieux §MSSA=Methicillin-susceptible Staphylococcus aureus. Clinical efficacy of TEFLARO in treating CABP due to MRSA has not been studied.